Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.

ABSTRACT: RNA interference (RNAi)-based therapeutics have been used to silence the expression of targeted pathological genes. Small interfering RNA (siRNAs) and microRNA (miRNAs) inhibitor have performed this function. However, short half-life, poor cellular uptake, and nonspecific distribution of small RNAs call for the development of novel delivery systems to facilitate the use of RNAi. We developed a novel cationic liquid crystalline nanoparticle (CLCN) to efficiently deliver synthetic siRNAs and miRNAs. CLCNs were prepared by using high-speed homogenization and assembled with synthetic siRNA or miRNA molecules in nuclease-free water to create CLCN/siRNA or miRNA complexes. The homogeneous and stable CLCNs and CLCN-siRNA complexes were about 100 nm in diameter, with positively charged surfaces. CLCNs are nontoxic and are taken up by human cells though endocytosis. Significant inhibition of gene expression was detected in transiently transfected lung cancer H1299 cells treated with CLCNs/anti-GFP complexes 24 hours after transfection. Biodistribution analysis showed that the CLCNs and CLCNs-RNAi complexes were successfully delivered to various organs and into the subcutaneous human lung cancer H1299 tumor xenografts in mice 24 hours after systemic administration. These results suggest that CLCNs are a unique and advanced delivery system capable of protecting RNAi from degradation and of efficiently delivering RNAi in vitro and in vivo.

SUBMITTER: Gentile E

PROVIDER: S-EPMC5564640 | biostudies-other | 2017 Jul

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges.

Project description:RNA interference (RNAi) is an evolutionarily conserved, endogenous process for post-transcriptional regulation of gene expression. Although RNAi therapeutics have recently progressed through the pipeline toward clinical trials, the application of these as ideal, clinical therapeutics requires the development of safe and effective delivery systems. Inspired by the immense progress with nanotechnology in drug delivery, efforts have been dedicated to the development of nanoparticle-based RNAi delivery systems. For example, a precisely engineered, multifunctional nanocarrier with combined passive and active targeting capabilities may address the delivery challenges for the widespread use of RNAi as a therapy. Therefore, in this review, we introduce the major hurdles in achieving efficient RNAi delivery and discuss the current advances in applying nanotechnology-based delivery systems to overcome the delivery hurdles of RNAi therapeutics. In particular, some representative examples of nanoparticle-based delivery formulations for targeted RNAi therapeutics are highlighted.

| S-EPMC3649006 | biostudies-literature

Self-Assembled Cubic Liquid Crystalline Nanoparticles for Transdermal Delivery of Paeonol.

Project description:BackgroundThe aim of this study was to optimize the preparation method for self-assembled glyceryl monoolein-based cubosomes containing paeonol and to characterize the properties of this transdermal delivery system to improve the drug penetration ability in the skin.Material and methodsIn this study, the cubic liquid crystalline nanoparticles loaded with paeonol were prepared by fragmentation of glyceryl monoolein (GMO)/poloxamer 407 bulk cubic gel by high-pressure homogenization. We evaluated the Zeta potential of these promising skin-targeting drug-delivery systems using the Malvern Zeta sizer examination, and various microscopies and differential scanning calorimetry were also used for property investigation. Stimulating studies were evaluated based on the skin irritation reaction score standard and the skin stimulus intensity evaluation standard for paeonol cubosomes when compared with commercial paeonol ointment. In vitro tests were performed on excised rat skins in an improved Franz diffusion apparatus. The amount of paeonol over time in the in vitro penetration and retention experiments both was determined quantitatively by HPLC.ResultsStimulating studies were compared with the commercial ointment which indicated that the paeonol cubic liquid crystalline nanoparticles could reduce the irritation in the skin stimulating test. Thus, based on the attractive characteristics of the cubic crystal system of paeonol, we will further exploit the cosmetic features in the future studies.ConclusionsThe transdermal delivery system of paeonol with low-irritation based on the self-assembled cubic liquid crystalline nanoparticles prepared in this study might be a promising system of good tropical preparation for skin application.

| S-EPMC4632989 | biostudies-literature

Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics.

Project description:In recent years, RNA interference (RNAi) therapeutics, most notably with lipid nanoparticle-based delivery systems, have advanced into human clinical trials. The results from these early clinical trials suggest that lipid nanoparticles (LNPs), and the novel ionizable lipids that comprise them, will be important materials in this emerging field of medicine. A persistent theme in the use of materials for biomedical applications has been the incorporation of biodegradability as a means to improve biocompatibility and/or to facilitate elimination. Therefore, the aim of this work was to further advance the LNP platform through the development of novel, next-generation lipids that combine the excellent potency of the most advanced lipids currently available with biodegradable functionality. As a representative example of this novel class of biodegradable lipids, the lipid evaluated in this work displays rapid elimination from plasma and tissues, substantially improved tolerability in preclinical studies, while maintaining in vivo potency on par with that of the most advanced lipids currently available.

| S-EPMC3734658 | biostudies-other

Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms.

Project description:Lipid nanoparticles (LNPs) have proven to be highly efficient carriers of short-interfering RNAs (siRNAs) to hepatocytes in vivo; however, the precise mechanism by which this efficient delivery occurs has yet to be elucidated. We found that apolipoprotein E (apoE), which plays a major role in the clearance and hepatocellular uptake of physiological lipoproteins, also acts as an endogenous targeting ligand for ionizable LNPs (iLNPs), but not cationic LNPs (cLNPs). The role of apoE was investigated using both in vitro studies employing recombinant apoE and in vivo studies in wild-type and apoE(-/-) mice. Receptor dependence was explored in vitro and in vivo using low-density lipoprotein receptor (LDLR(-/-))-deficient mice. As an alternative to endogenous apoE-based targeting, we developed a targeting approach using an exogenous ligand containing a multivalent N-acetylgalactosamine (GalNAc)-cluster, which binds with high affinity to the asialoglycoprotein receptor (ASGPR) expressed on hepatocytes. Both apoE-based endogenous and GalNAc-based exogenous targeting appear to be highly effective strategies for the delivery of iLNPs to liver.

| S-EPMC2911264 | biostudies-literature

Silver Nanoparticles with Liquid Crystalline Ligands Based on Lactic Acid Derivatives.

Project description:We have prepared and studied silver nanoparticles functionalized with ligands based on lactic acid derivatives. Several types of hybrid systems that differed in the size of silver nanoparticles as well as the length of surface ligands were analyzed. Transmission electron microscopy (TEM) observation provided information about the size and shape of nanoparticles and proved good homogeneity of studied systems. By dynamic light scattering (DLS) measurements, we have measured the size distribution of nanoparticle systems. Plasmonic resonance was detected at around 450 nm. For two hybrid systems, the mesomorphic behaviour has been demonstrated by x-ray measurements. The observed thermotropic liquid crystalline phases reveal lamellar character. We have proposed a model based on self-assembly of intercalated liquid crystalline ligands.

| S-EPMC6723366 | biostudies-literature

Polysorbate cationic synthetic vesicle for gene delivery.

Project description:Synthetic nonionic surfactant vesicles (niosomes) are a colloidal system with closed bilayer structures, displaying distinct advantages in stability and cost compared with liposomes. In this article, polysorbate cationic niosomes (PCNs) were developed as gene carriers. The PCNs comprised nonionic surfactants (i.e., polysorbates) and a cationic cholesterol, and were synthesized using a film hydration method. The niosomes thus prepared possessed a regular morphology, and a particle size of 100 ? 200 nm, and a zeta potential of +30 ? 45 mV. The PCNs showed great physical stability over the course of 4 weeks at room temperature. The binding capacity of PCNs toward oligodeoxynucleotides (ODN) was assessed by a gel retardation approach, which demonstrated that the ionic complexes were formed when ± charge ratio reached to 4 or greater. Gene transfer study showed that the PCNs exhibited a high efficiency in mediating cellular uptake and transferred DNA expression. Based on these findings, PCNs may offer the potential to function as an effective gene delivery system.

| S-EPMC3065677 | biostudies-literature

Bioelectricity for Drug Delivery: The Promise of Cationic Therapeutics.

Project description:Biological systems overwhelmingly comprise charged entities generating electrical activity that can have significant impact on biological structure and function. This intrinsic bio-electrical activity can also be harnessed for overcoming the tissue matrix and cell membrane barriers, which have been outstanding challenges for targeted drug delivery, by using rationally designed cationic carriers. The weak and reversible long-range electrostatic interactions with fixed negatively charged groups facilitate electro-diffusive transport of cationic therapeutics through full-tissue thickness to effectively reach intra-tissue, cellular, and intracellular target sites. This article presents a perspective on the promise of using rationally designed cationic biomaterials in targeted drug delivery, the underlying charge-based mechanisms, and bio-transport phenomena while addressing outstanding concerns around toxicity and methods to mitigate them. We also discuss electrically charged drugs that are currently being evaluated in clinical trials and identify areas of further development that have the potential to usher in new treatments.

| S-EPMC7313641 | biostudies-literature

Liquid crystalline cellulose-based nematogels.

Project description:Physical properties of composite materials can be pre-engineered by controlling their structure and composition at the mesoscale. However, approaches to achieving this are limited and rarely scalable. We introduce a new breed of self-assembled nematogels formed by an orientationally ordered network of thin cellulose nanofibers infiltrated with a thermotropic nematic fluid. The interplay between orientational ordering within the nematic network and that of the small-molecule liquid crystal around it yields a composite with highly tunable optical properties. By means of combining experimental characterization and modeling, we demonstrate submillisecond electric switching of transparency and facile responses of the composite to temperature changes. Finally, we discuss a host of potential technological uses of these self-assembled nematogel composites, ranging from smart and privacy windows to novel flexible displays.

| S-EPMC5562421 | biostudies-other

Liquid Crystalline Network Composites Reinforced by Silica Nanoparticles.

Project description:Liquid crystalline networks (LCNs) are a class of polymers, which are able to produce mechanical actuation in response to external stimuli. Recent creation of LCNs with exchangeable links (xLCNs) makes LCNs easy moldable. As the xLCNs need to be shaped at a high temperature, it is important to enhance their thermal and mechanical properties. In this paper, a series of xLCNs/SiO? composites containing 1%-7% SiO? nanoparitcles (SNP) were prepared and their thermal and mechanical properties were examined. The results show that xLCNs/SNP composites have lower liquid crystalline-isotropic phase transition temperature and higher decomposition temperature than pure LCN. The tensile strength and the elongation at break of xLCNs at high temperatures were also enhanced due to the addition of SNPs.

| S-EPMC5455816 | biostudies-other

Delivery of RNAi Therapeutics to the Airways-From Bench to Bedside.

Project description:RNA interference (RNAi) is a potent and specific post-transcriptional gene silencing process. Since its discovery, tremendous efforts have been made to translate RNAi technology into therapeutic applications for the treatment of different human diseases including respiratory diseases, by manipulating the expression of disease-associated gene(s). Similar to other nucleic acid-based therapeutics, the major hurdle of RNAi therapy is delivery. Pulmonary delivery is a promising approach of delivering RNAi therapeutics directly to the airways for treating local conditions and minimizing systemic side effects. It is a non-invasive route of administration that is generally well accepted by patients. However, pulmonary drug delivery is a challenge as the lungs pose a series of anatomical, physiological and immunological barriers to drug delivery. Understanding these barriers is essential for the development an effective RNA delivery system. In this review, the different barriers to pulmonary drug delivery are introduced. The potential of RNAi molecules as new class of therapeutics, and the latest preclinical and clinical studies of using RNAi therapeutics in different respiratory conditions are discussed in details. We hope this review can provide some useful insights for moving inhaled RNAi therapeutics from bench to bedside.

| S-EPMC6272875 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data